Association of HER2 overexpression and prognosis in small (T1N0) primary breast cancers

• Verfasst von: Rom, Joachim [VerfasserIn]
• Verfasst von: Schumacher, Claudia [VerfasserIn]
• Verfasst von: Gluz, Oleg [VerfasserIn]
• Verfasst von: Höfler, Josef [VerfasserIn]
• Verfasst von: Eidt, Sebastian [VerfasserIn]
• Verfasst von: Domschke, Christoph [VerfasserIn]
• Verfasst von: Marmé, Frederik [VerfasserIn]
• Verfasst von: Nitz, Ulrike [VerfasserIn]
• Verfasst von: Sohn, Christof [VerfasserIn]
• Verfasst von: Schneeweiss, Andreas [VerfasserIn]
• Titel: Association of HER2 overexpression and prognosis in small (T1N0) primary breast cancers
• Verf.angabe: Joachim Rom, Claudia Schumacher, Oleg Gluz, Josef Höfler, Sebastian Eidt, Christoph Domschke, Frederik Marmé, Ulrike Nitz, Christof Sohn, Andreas Schneeweiss
• E-Jahr: 2013
• Jahr: June 22, 2013
• Umfang: 7 S.
• Fussnoten: Gesehen am 19.01.2022
• Titel Quelle: Enthalten in: Breast care
• Ort Quelle: Basel : Karger, 2006
• Jahr Quelle: 2013
• Band/Heft Quelle: 8(2013), 3 vom: Juni, Seite 208-214
• ISSN Quelle: 1661-3805
• DOI: doi:10.1159/000352094
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1786454688

Abstract

Background: There is some controversy regarding the precise role and need for adjuvant therapy in patients with pT1a/pT1bN0 breast cancer, although studies have indicated that a HER2-positive status is one of the most powerful poor prognostic factors. Patients and Methods: We retrospectively evaluated disease-free survival (DFS), distant disease-free survival (DDFS), and overall survival (OS) among 960 patients diagnosed between 2000 and 2008 with T1N0 primary breast cancer treated at 3 German centers, and determined prognostic risk factors. Univariate analysis was used to determine associations with potential risk factors. Results: With a median follow-up of 23 months, DFS was 94.8%, DDFS 96.3%, and OS 97.5%. Risk factors for decreased 1-year DFS were: peritumoral lymphatic invasion (L1) (p = 0.031), negative hormone receptor status (p = 0.003), non-use of hormonal therapy (p = 0.001), and a positive HER2 status (p = 0.003). Amongst the HER2-positive patients only 2.7% (n = 1/37) of those treated with trastuzumab had a DFS event compared with 20% (n = 10/50) without trastuzumab. Conclusion: Patients with HER2-positive T1 breast cancer should be considered for inclusion in prospective trials of trastuzumab in combination with chemotherapy to determine the risk-to-benefit ratio and association with other prognostic factors.